Mekonos

We are a Silicon Valley chip technology startup aimed primarily toward cancer immunotherapy, gene engineering and drug development.

In our mission to enable industrial scale genome editing for therapeutics and therefore making gene therapies universally accessible, Mekonos is developing a new approach for cell engineering using a proprietary silicon chip technology (KAREL) that delivers molecules into potentially, millions of individual cells. This will see a dramatic breakthrough in the genetic engineering treatment of diseases such as cancers. Instead of the more traditional method of using viruses which have major safety risks and are very expensive, our safe, cheaper and easy-to-use silicon based technology, when fully developed will result in an estimated 20-30x cost reduction and a 1000x throughput improvement over competitors. Plus there is no direct involvement with the FDA as we are neither diagnostics nor therapeutics.